Cardiff Oncology's Onvansertib Receives Orphan Drug Status for CMML

The FDA has granted Orphan Drug Designation to Cardiff Oncology's onvansertib for chronic myelomonocytic leukemia (CMML). This designation aims to incentivize the development of treatments for rare diseases, potentially accelerating the drug's path to market for patients with this condition.